CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
Megestrol Acetatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00483327
NCT00483327Phase 2Completed
CompareCT.gov

Prospective Trial of Conservative Management of Atypical Endometrial Hyperplasia and Well to Moderately Differentiated Endometrial Carcinoma Using Megestrol Acetate

NYU Langone Health·interventional·Posted Jun 7, 2007·Updated Apr 4, 2018

In Brief

A Phase 2 clinical trial evaluating Megestrol Acetate for Atypical Endometrial Hyperplasia and Endometrial Carcinoma. Completed, enrolled 31 participants across 2 sites.

Detailed Summary

The purpose of this trial is to study the efficacy, toxicity, and tolerability of a standard hormonal regimen of Megestrol Acetate (Megace) in the treatment of Atypical Endometrial Hyperplasia or well to moderately differentiated endometrial carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtypical Endometrial Hyperplasia, Endometrial Carcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 7, 2007
Enrollment StartJun 1, 2007
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 19.1 years ago

Interventions

Megestrol Acetatedrug